WHO Warns on Nicotine Pouches in 2025: Impact on Indian Pharma Regulations & Career Opportunities

Picture this: you're scrolling through LinkedIn at midnight, and a WHO news alert catches your eye. The World Health Organization just issued a major warning about nicotine pouches targeting youth, and within hours, regulatory affairs professionals across India are already discussing what this means for policy changes. Meanwhile, you're wondering if this news item could somehow help you land that regulatory affairs job you've been eyeing since graduation.

The WHO's May 2025 warning on nicotine pouches isn't just another health advisory buried in bureaucratic language. It's a signal that India's regulatory framework around nicotine products is about to get significantly more complex, and that complexity creates jobs. For B.Pharm and M.Pharm freshers who understand these developments, this is the kind of niche expertise that makes you stand out in interviews at IQVIA, Novartis, or any CRO with a regulatory affairs division.

Let me walk you through what's actually happening, why it matters for Indian pharma regulation, and how you can position yourself to benefit from these changes.

Business professional at the desk examining a software development agreement document. — Photo by cottonbro studio on Pexels

Understanding WHO's Nicotine Pouch Warning: What Changed in 2025

The World Health Organization released a strongly worded advisory in May 2025 specifically targeting nicotine pouch manufacturers for aggressive youth marketing. This isn't the first time WHO has raised concerns about novel nicotine products, but the language this time is notably sharper. The advisory explicitly calls out brands for using social media influencers, flavored products, and sleek packaging designed to appeal to teenagers and young adults.

WHO's core concerns center on three issues. First, nicotine pouches deliver highly addictive nicotine without any combustion, which makes them seem "safer" but doesn't eliminate addiction risk. Second, the products exist in a regulatory grey zone in most countries, neither classified as tobacco nor as pharmaceutical products. Third, the marketing strategies mirror what cigarette companies used decades ago before advertising restrictions, essentially creating a new generation of nicotine-dependent consumers.

The global response has been uneven. Sweden, where nicotine pouches originated, has relatively permissive regulations. The UK treats them as consumer products with age restrictions. The US FDA is still determining how to classify them, caught between treating them as tobacco products or drug delivery devices. Several African and Southeast Asian countries have moved toward outright bans following WHO guidance.

Current Regulatory Landscape for Nicotine Pouches in India

India's tobacco control framework rests primarily on the Cigarettes and Other Tobacco Products Act (COTPA) of 2003, which was designed for traditional tobacco products. The law covers cigarettes, bidis, gutka, and pan masala containing tobacco. What it doesn't adequately address is tobacco-free nicotine products, which is exactly where nicotine pouches sit.

This creates a genuine regulatory puzzle. Nicotine pouches contain pharmaceutical-grade nicotine but no tobacco leaf. They're not cigarettes. They're not gutka. They don't fit neatly into COTPA's definitions, which means enforcement becomes inconsistent and manufacturers can argue they're not covered by existing tobacco restrictions.

The Central Drugs Standard Control Organisation (CDSCO) has jurisdiction over drugs and cosmetics, and nicotine is listed in Schedule H1 as a prescription drug. But nicotine pouches aren't marketed as medicines or smoking cessation aids. They're sold as lifestyle products. This creates a jurisdictional gap where neither the tobacco control authorities nor the drug regulatory authorities have clear oversight.

Several states have taken independent action. Karnataka, Maharashtra, and Gujarat have issued notifications restricting or banning nicotine pouches at the state level. But without central legislation, enforcement remains patchy, and products continue to be available through online channels and in states without specific bans.

Expected Regulatory Changes Following WHO Warning

The WHO warning will almost certainly accelerate regulatory action in India, though the timeline remains uncertain. Based on how India has historically responded to WHO advisories on tobacco products, we can expect movement within 12-18 months.

The most likely outcome is an amendment to COTPA that expands the definition of tobacco products to include tobacco-free nicotine delivery devices. This would bring nicotine pouches under the same advertising restrictions, health warnings, and sales limitations that apply to cigarettes. Alternatively, the government could classify nicotine pouches as drugs under the Drugs and Cosmetics Act, which would require manufacturers to obtain drug licenses and potentially restrict sales to pharmacies.

Import restrictions are probable regardless of which regulatory path India chooses. Currently, most nicotine pouches sold in India are imported. New regulations would likely require import licenses, quality testing, and compliance with Indian packaging and labeling requirements. This creates compliance work that regulatory affairs professionals will need to manage.

Manufacturing licenses present another area of change. If nicotine pouches are classified as drugs, manufacturers will need to comply with Schedule M (Good Manufacturing Practices) requirements. If classified under COTPA, they'll need to navigate tobacco product licensing. Either path requires regulatory expertise.

Impact on Indian Pharmaceutical Industry

The regulatory changes will affect different parts of the pharma industry in different ways. Companies manufacturing legitimate nicotine replacement therapy (NRT) products like patches, gums, and lozenges will likely benefit from clearer distinction between medical products and recreational nicotine pouches. Cipla, Sun Pharma, and several smaller players have NRT portfolios that could see increased demand if recreational alternatives face restrictions.

Research and development implications are mixed. On one hand, tighter regulation of nicotine pouches could increase interest in developing approved smoking cessation products with better efficacy data. On the other hand, companies exploring novel nicotine delivery systems for harm reduction will face higher regulatory hurdles and longer approval timelines.

The compliance cost burden will fall heavily on smaller manufacturers and importers. Meeting new labeling requirements, obtaining necessary licenses, and maintaining regulatory documentation requires dedicated personnel. This is where the job opportunities emerge. Companies that previously operated with minimal regulatory oversight will need to build or expand regulatory affairs teams.

Export dynamics are interesting to consider. India could potentially become a manufacturing hub for nicotine products destined for markets with less restrictive regulations, while maintaining tight domestic controls. This would create regulatory affairs roles focused on understanding multiple jurisdictions and managing export documentation.

Career Implications for Pharma Freshers in Regulatory Affairs

Regulatory affairs is already one of the better entry points for pharma freshers, and this WHO warning creates a specific niche where informed candidates can differentiate themselves. The demand isn't just for people who understand general regulatory processes. It's for people who understand tobacco control policy, nicotine product classification, and how international guidelines translate into Indian law.

The job roles emerging from this regulatory shift include regulatory compliance officers who ensure company practices align with evolving requirements, policy analysts who track regulatory developments and advise management, and clinical research associates working on smoking cessation product trials. There's also growing demand for pharmacovigilance specialists monitoring adverse events related to nicotine products.

Salary expectations in regulatory affairs for freshers typically range from ₹3-5 lakhs annually at CROs and mid-size pharma companies. With specialization in tobacco and nicotine regulation, you can potentially command the higher end of this range. After 2-3 years of experience in this niche, salaries typically reach ₹6-9 lakhs, with senior regulatory affairs managers earning ₹12-18 lakhs at major companies.

The career trajectory is genuinely promising. Regulatory affairs professionals with expertise in contested product categories (where regulations are evolving rapidly) become valuable because they can navigate uncertainty. Companies pay premiums for people who can anticipate regulatory changes rather than just react to them.

Key Competencies Pharma Graduates Need to Master

Understanding international regulatory frameworks is essential because Indian regulations increasingly align with global standards. You should be familiar with WHO's Framework Convention on Tobacco Control (FCTC), FDA's approach to tobacco and nicotine products, and EMA guidelines on nicotine replacement therapies. This doesn't mean memorizing every detail, but understanding the principles and knowing where to find specific information.

Indian regulatory knowledge remains foundational. You need to understand CDSCO's drug approval process, the distinction between Schedule H and Schedule H1 drugs, and the licensing requirements for different product categories. The Drugs and Cosmetics Act and COTPA should be familiar territory. If you haven't read the actual text of these laws, now is the time.

Documentation and compliance skills matter more than many freshers realize. Regulatory affairs is fundamentally about paperwork done correctly. You need to write clearly, organize information logically, and maintain meticulous records. Companies test for this in interviews by giving you sample regulatory scenarios and asking how you would document the process.

Pharmacovigilance expertise increasingly overlaps with regulatory affairs. Understanding adverse event reporting, signal detection, and post-market surveillance makes you more versatile. Many regulatory affairs roles at CROs include pharmacovigilance responsibilities, especially at the entry level.

Preparing for Regulatory Affairs Interviews in This Domain

Interviewers will test whether you actually follow regulatory developments or just claim to. When asked about current issues in tobacco regulation, you should be able to discuss the WHO's May 2025 warning, mention specific concerns about youth marketing, and explain why nicotine pouches present classification challenges in India. Generic answers about "staying updated with industry news" won't impress anyone.

Common interview questions include: "How would you classify nicotine pouches under Indian law?" "What's the difference between COTPA and the Drugs and Cosmetics Act in terms of scope?" "If a company wanted to launch a new nicotine product in India, what regulatory pathway would you recommend?" Practice answering these with specific references to actual regulations.

Case study preparation helps significantly. Take a hypothetical scenario, perhaps a company wanting to import nicotine pouches for sale in India, and work through the regulatory requirements step by step. What licenses would be needed? What labeling requirements apply? What are the penalties for non-compliance? Being able to walk through this analysis demonstrates practical thinking.

Demonstrating awareness means citing specific sources. "According to WHO's May 2025 advisory..." or "COTPA Section 5 prohibits..." shows you've done actual research rather than skimming headlines.

Action Steps for B.Pharm/M.Pharm Freshers

Start following CDSCO notifications directly. The official website isn't user-friendly, but you can sign up for email alerts. Also follow the Ministry of Health and Family Welfare for policy announcements. WHO's tobacco control pages are worth bookmarking. Make this a weekly habit, not something you do only before interviews.

Skill development should be targeted. The Diploma in Regulatory Affairs from NIPER or similar institutions provides solid grounding. Online courses from platforms like Coursera or edX covering pharmaceutical regulations can supplement formal education. Focus on courses that include Indian regulatory content, not just US FDA-centric material.

Networking through professional bodies creates opportunities that job boards don't. The RAPS India chapter hosts events in Hyderabad, Bengaluru, and Mumbai. The Indian Pharmaceutical Association has a regulatory affairs section. LinkedIn groups focused on Indian pharma regulatory affairs are active. Engage genuinely, ask questions, and share relevant articles you've found.

Your resume should highlight relevant coursework explicitly. If you took a paper on pharmaceutical jurisprudence, list it. If you did a project on drug regulatory submissions, describe it. If you've read and understood COTPA, mention it in your cover letter. Regulatory affairs hiring managers look for evidence that you've already started building domain knowledge.

Target companies with strong regulatory departments: IQVIA, Parexel, Syneos Health, and Covance have significant regulatory affairs operations in India. On the pharma side, Cipla, Sun Pharma, Dr. Reddy's, and Biocon maintain robust regulatory teams. Accenture Life Sciences and Cognizant Life Sciences handle regulatory work for multiple clients. Apply to these companies specifically, and tailor your application to mention their regulatory affairs work.

The path from fresher to employed regulatory affairs professional typically takes 4-8 months of active searching. The median number of applications before landing an interview is around 35-40. This isn't meant to discourage you. It's meant to help you plan realistically. If you're at application 25 with no responses, you're not failing. You're on track.

Understanding regulatory developments like the WHO nicotine pouch warning gives you something concrete to discuss in interviews that most candidates won't have. It shows initiative, genuine interest, and the kind of proactive thinking that regulatory affairs roles require. Build your pharma CV to highlight this regulatory knowledge on ClinPath's free CV builder, and make sure your application materials reflect that you're not just looking for any job. You're specifically interested in regulatory affairs during an interesting time in the field.